All News

Article

AI meets Rheumatology: ChatGPT and patient response optimization

Bella Mehta, MBBS, MS Jun 12, 2024

Large language models, such as ChatGPT, are advanced systems trained on vast amounts of text data, far exceeding what a human can read in a lifetime, to understand and generate human-like language. With these tools at our disposal, they are inevitably making their way into healthcare. One notable example is response optimization for SLE patients, as highlighted in abstract #0989.

Reminder of relevance of #Rheumatoid factor ⬆️RF also predicts cardiovascular events ⚠️ ⬆️disease activity ❗️Worse outcomes #EULAR2024 #RF #RA https://t.co/kXwh682ONp

https://twitter.com/gurdeep_dulay/status/1800935105009000749/photo/1

OP0048 Impressive CLASI (lupus skin index score) with #deucravacitinib - data presented by Dr C Arriens #EULAR24 @RheumNow #WiR https://t.co/EuQdwuolN6

https://twitter.com/KDAO2011/status/1800913576238145785/photo/1

What is new in RA at #EULAR2024? Below 👇🏻 my article summarising some of the exciting new MoA, therapeutic strategies and drugs that might (or not) shape RA future! https://t.co/ttYdElWlBY @RheumNow

Encurtador de Link

🚨New(ish) MoA in RA Abiprubart anti-CD40 mAb Blocks T cell activation Reduction DAS28-CRP Wk 12 -2.2 vs. -1.6 PBO Small sample n=25 per gpe Safety profile acceptable To be continued... Abstr#OP0036 #EULAR2024 @RheumNow https://t.co/su4L7A7nGJ

https://twitter.com/AurelieRheumo/status/1800933979584917902/photo/1

Substudy of SELECT-COMPARE trial Week 60 immunogenicity RZV RA treated UPA 15 mg + MTX ✔️ HUmorale response 71% ✔️ Cellular response 65% ✔️ No serious AEs ✔️ One event of HZ occurred during follow up Abstr#OP0020 #EULAR2024 @RheumNow https://t.co/8OMwGuIZFx

https://twitter.com/AurelieRheumo/status/1800934293604098449/photo/1

Novel B cell depleters! Bispecific T cell engagers (BiTEs) being studied for #SLE & #RA as a way to get CAR-T cell like responses but more accessible w/less risk for CK release syndrome. #EULAR24 T cell-engaging therapies — BiTEs and beyond | Nature Reviews Clinical Oncology

I chaired great debate at #EULAR2025 - JAK Inhibitor Special Warnings: can observational data debunk an RCT? Drs Janet Pope(NO) vs David Liew(YES). Voting suggests most are concerned about JAK warnings, but Liew won by converting a minority his way @janetbirdope @Drdavidliew https://t.co/bV1JdO7c4e

Nordic country analysis of mortality in RA (n 1145), RA-ILD (239), population ILD (378) & nl controls (1890) shows most mortality in pop ILD (HR 8.3), but less in RA-ILD (HR 3.6). Why is death less in latter; could it be RA therapies? Abstr #POS0022 # EULAR2025 https://t.co/wFZq49rIiW

✨ Powerful stories shared at the #EULAR2024 Opening Ceremony including from #PARE Chair @fibrofella https://t.co/Jzfk9LrhV4

https://twitter.com/fibrofella/status/1800852458249576588

EULAR 2024 kicked off with a fantastic debate between Janet Pope and David Liew - ‘JAK inhibitor special warnings: Can observational data debunk an RCT?’ A thought-provoking discussion summarising all aspects of the ongoing conversation on JAKi use in high-risk patients! https://t.co/MzW3jSSCfr

More data from Jak-pot, the real-world multinational RA study, this time looking at infection in 14 national registries JAKi (vs TNFi) had no signal for general/serious infection (excluding HZ) Somewhat reassuring post-ORAL Surveillance infection data #EULAR2024 OP0092 @RheumNow https://t.co/ocAbc4NiV2

https://twitter.com/drdavidliew/status/1800922236372791605/photo/1

Extra musculoskeletal manifestations (EMMs) in spondyloarthritis #EULAR2024 OP0085 @RheumNow https://t.co/yRxPmMYLxn

https://twitter.com/synovialjoints/status/1800920604838924393/photo/1

#EULAR2024 Please find my article on a preview of interesting abstract to look out for for #lupus #SLE therapies at this year’s congress @RheumNow https://t.co/TEtrDWq3BF https://t.co/1zIIxsaeL2

Increase in mSASSS over time was greater with increasing comorbidity burden. Increasing comorbidity burden is independently associated with greater radiographic progression #EULAR2024 OP0103 @RheumNow https://t.co/j7UblASUvC

SpA patients with IBD, compared to those without IBD, were less frequently male and more frequently HLA-B27 negative, had higher rates of uveitis and lower rates of psoriasis, exhibited more structural damage on SI joints in the METEOR cohort #EULAR2024 OP0085 @RheumNow https://t.co/c2KdzIumc4

https://twitter.com/synovialjoints/status/1800918388690108811/photo/1

Swap or Cycle? Study OP0081 show after failure to a first TNFi in patients with axSpA, the drug retention rate was higher in the cycle strategy compared to the swap (IL-17i) strategy. No difference in the disease activity between cycle and swap strategy #EULAR2024 @RheumNow https://t.co/vr5DvNOb21

https://twitter.com/synovialjoints/status/1800915408175927352/photo/1

Check out our coverage all #EULAR2024! https://t.co/Be3O5npnbi https://t.co/fcg99zkbLi

EULAR 2024 | RheumNow

Humira Clobbers Biosimilars in Battle for Part D Coverage Researchers found nearly all Medicare Part D plans cover original adalimumab (Humira), but only about half cover approved biosimilars. https://t.co/mpkypge1rE https://t.co/qRvtg4IM8c

Humira Clobbers Biosimilars in Battle for Part D Coverage | RheumNow

Treatment intensification is associated with a higher ASDAS cut-off value than the recommended one (≥2.1). Rheumatologists may feel this is too stringent and use a higher ASDAS value for treatment intensification #EULAR2024 Abstract 0060 @RheumNow https://t.co/54vZUz7IEz

https://twitter.com/synovialjoints/status/1800913941041967564/photo/1

Topics

All News

AI meets Rheumatology: ChatGPT and patient response optimization

Do you get our email newsletter?